EMA releases new heart attack medicine guidance

Published: 21-Nov-2014
Regulatory Cardiovascular

Major developments have taken place since the last guidance was issued in 2000 and 2003


Revised draft guidance on the assessment of medicines designed to treat heart attacks has been released by the European Medicines Agency (EMA).

The Agency said since its last guidance in 2000 and 2003, 'major developments have taken place in the definitions, diagnosis, interventions and management of acute coronary syndrome'.

See more

You may also like

Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Read more
Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    NICE approval is not enough: why the UK’s next medicines challenge is operational delivery A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
  2. Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
  3. FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions
  4. Lonza and Oxford Nanopore launch direct RNA sequencing solution for GMP mRNA quality control New nanopore sequencing and machine learning workflow simplifies multi-attribute QC testing for mRNA therapeutics
  5. Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NICE approval is not enough: why the UK’s next medicines challenge is operational delivery

A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
Regulatory

What to expect from a regulatory inspection: An NSF expert guide

Prepare with confidence. NSF’s expert guide shows what inspectors look for, common pitfalls and how to ensure lasting inspection readiness
Manufacturing

Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe

After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
Manufacturing

Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics

All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing
Manufacturing

FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant

A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions
Subscribe now